Synapse Alterations in MSA Patients

NCT06221644 | Completed

• 1 other identifier: 20240113
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Synaptic loss has been implicated in various neurodegenerative conditions, yet its understanding in multiple system atrophy (MSA) remains limited. The aim of this study was to examine spatial synaptic density alterations in MSA patients and evaluate the potential of \[18F\]SynVesT-1 PET as an imaging biomarker for MSA in both diagnosis and monitoring disease severity.

Conditions

Multiple System Atrophy

Keywords

synaptic density; PET; SV2A

Outcome Measures

Primary Outcomes (2)

• Spatial synaptic density alterations in MSA patients

  To examine spatial synaptic density alterations in MSA patients

  10 months

• [18F]SynVesT-1 PET as an imaging biomarker for MSA

  evaluate the potential of \[18F\]SynVesT-1 PET as an imaging biomarker for MSA

  10 months

Study Arms (2)

MSA patients group

The patient cohort consisted of 30 MSA-C and 30 MSA-P cases, diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists

Diagnostic Test: [18F]SynVesT-1 PET/CT

healthy controls (HCs) group

30 gender and age-matched HCs were included

Diagnostic Test: [18F]SynVesT-1 PET/CT

Interventions

[18F]SynVesT-1 PET/CT DIAGNOSTIC_TEST

60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment

MSA patients group; healthy controls (HCs) group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

60 patients diagnosed with MSA were recruited. The patient cohort consisted of 30 MSA-C and 30 MSA-P cases, diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists. Additionally, 30 gender and age-matched HCs were included.

You may qualify if:

• The MSA patient were diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists.

You may not qualify if:

• encompassed MRI contraindications, a history of epilepsy, stroke, or brain surgery, intracranial organic lesions unrelated to MSA, usage of levetiracetam or brivaracetam, and a history of alcohol or drug abuse

Sponsors & Collaborators

• Xiangya Hospital of Central South University: lead

Study Sites (1)

Jian Li

Changsha, Hunan, 410008, China

Location

MeSH Terms

Conditions

Multiple System Atrophy

Condition Hierarchy (Ancestors)

Primary Dysautonomias; Autonomic Nervous System Diseases; Nervous System Diseases; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Shuo Hu

  Shuo Hu

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2024
• First Posted: January 24, 2024
• Study Start: April 1, 2022
• Primary Completion: October 30, 2022
• Study Completion: November 25, 2022
• Last Updated: January 25, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)